The premorbid level of
selenoprotein P in plasma from subjects with
cancer at different sites was compared with that from control subjects in a nested case-control study. A health screening of 12,500 middle-aged men was performed during 1974-1982 in Malmö, Sweden, and from the 400
cancer cases that were identified during follow-up until the end of 1988, 302 plasma samples were available for analysis of
selenoprotein P. Two living controls per case of the same screening day and age were chosen.
Selenoprotein P levels in subgroups of major
cancer sites were lower in cases than in controls for the respiratory tract (1.20 and 1.30 arbitrary units, respectively; p < 0.05)
cancer group. The odds ratio for overall
cancer risk in the lowest quintile of
selenoprotein P level compared with that in the highest was 5.2 [p (for trend) = 0.01]. In subgroups of major
cancer sites, the odds ratios for
cancer risk in the lowest tertile compared with the highest were 6.0 [p (for trend) = 0.004] in the respiratory tract and 3.4 [p (for trend) = 0.002] in the digestive tract. In cases + controls,
selenoprotein P was lower in smokers than in nonsmokers (p < 0.05).
Selenoprotein P was significantly correlated to
plasma albumin, fasting
blood glucose, and body mass index and inversely correlated to plasma
alpha 1-antitrypsin and gamma-glutamyl
transferase. The results suggest that a low plasma
selenoprotein P level is associated with higher future risk of respiratory and digestive tract
cancer in middle-aged men.